Andrew Chapman AstraZeneca

Andrew Chapman, BEng, MBA, is a Senior Director at AstraZeneca in Biopharmaceutical Development, where he leads technology strategy and the evaluation, development and commercialisation of drug delivery technologies.

With over 21 years of experience developing breakthrough technologies for some of the world's largest pharmaceutical and medical technology companies, Andrew is known for his strategic thinking, clear communication, and adaptive leadership. Holding degrees in both engineering and business he is passionate about improving patients' lives through technological innovation.

Andrew's professional journey includes diverse roles ranging from project leadership to setting and executing organization-wide strategies, along with P&L responsibility for multimillion-dollar divisions. He has led strategic consulting projects in medical devices, connected devices, and digital health for industry leaders such as AbbVie, Roche, CSL Behring, Smith & Nephew, and Zimmer Biomet. Before joining AstraZeneca, Andrew served as Vice President at Sagentia and as Head of Digital Health at the UK government’s Digital Catapult.